Trial · NCT00770328

The Effects of Pentoxifylline on PAI-1 in an Obese Population

NCT00770328, Phase 4, Completed, Vanderbilt University; results first posted 2017-11-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. The Effects of Pentoxifylline on PAI-1 in an Obese Population. Trials, record NCT00770328. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00770328

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Effects of Pentoxifylline on PAI-1 in an Obese Population
NCT number: NCT00770328
Status: Completed
Phases: Phase 4
Enrollment: 37 participants, actual
Lead sponsor: Vanderbilt University
Conditions: Obesity
Interventions: Pentoxifylline, Placebo
First posted: 2008-10-10
Last updated: 2017-11-30
Results first posted: 2017-11-30

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Change in PAI-1 Level	Baseline and 8 weeks
Secondary	Change in CRP Level	Baseline and 8 weeks
Secondary	Change in TNF-alpha Level	Baseline and 8 weeks
Secondary	Changes in the Relationship Between PAI-1, CRP, and TNF-a With Therapy.	Baseline and 8 weeks

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in PAI-1 Level	Baseline and 8 weeks		ng/ml	MEAN
SECONDARY	Change in CRP Level	Baseline and 8 weeks		mg/dl	MEAN
SECONDARY	Change in TNF-alpha Level	Baseline and 8 weeks	TNF-a assay did not work properly. Meaningless data resulted including negative values which are impossible.
SECONDARY	Changes in the Relationship Between PAI-1, CRP, and TNF-a With Therapy.	Baseline and 8 weeks	Unable to complete analysis due to TNF-a assay failure (see Outcome measure #3)

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in PAI-1 Level	Pentoxifylline	Baseline	39.5	Standard Error 8.3	ng/ml
Change in PAI-1 Level	Placebo	Baseline	31.6	Standard Error 7.6	ng/ml
Change in PAI-1 Level	Pentoxifylline	8 Weeks	28.6	Standard Error 7.7	ng/ml
Change in PAI-1 Level	Placebo	8 Weeks	37.9	Standard Error 8.5	ng/ml
Change in CRP Level	Pentoxifylline	Baseline	5.2	Standard Error 2.5	mg/dl
Change in CRP Level	Placebo	Baseline	2.9	Standard Error 0.5	mg/dl
Change in CRP Level	Pentoxifylline	8 weeks	4.6	Standard Error 1.9	mg/dl
Change in CRP Level	Placebo	8 weeks	2.4	Standard Error 0.5	mg/dl

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pentoxifylline	22
Overall Study	STARTED	Placebo	15
Overall Study	COMPLETED	Pentoxifylline	9
Overall Study	COMPLETED	Placebo	11
Overall Study	NOT COMPLETED	Pentoxifylline	13
Overall Study	NOT COMPLETED	Placebo	4

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nausea/Vomiting	Gastrointestinal disorders	Pentoxifylline	11	22	11
other	Nausea/Vomiting	Gastrointestinal disorders	Placebo	0	15	0
other	Allergic Reaction	Immune system disorders	Pentoxifylline	0	22	0
other	Allergic Reaction	Immune system disorders	Placebo	1	15	1
other	Bloating	Gastrointestinal disorders	Pentoxifylline	0	22	0
other	Bloating	Gastrointestinal disorders	Placebo	1	15	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pentoxifylline
Total, all-cause mortality	Placebo
Total, other adverse events	Pentoxifylline	11	22
Total, other adverse events	Placebo	2	15
Total, serious adverse events	Pentoxifylline	0	22
Total, serious adverse events	Placebo	0	15

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Pentoxifylline vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00770328

GET https://conductscience.org/api/trials/v1/NCT00770328/registered

API reference For AI assistants